Results 221 to 230 of about 36,737 (275)

Comprehensive prognosis assessment of cardiovascular magnetic resonance parametric mapping in light chain amyloidosis. [PDF]

J Cardiovasc Magn Reson
Li X, Guo Y, Shen K, Huang S, Gao Y, Lin L, Wang J, Cao J, Cao X, Jin Z, Zhang Z, Varga-Szemes A, Schoepf UJ, Li J, Wang Y.   +14 more
europepmc   +1 more source

Supplementary Material for: Long-term outcomes in patients with renal systemic light chain amyloidosis

figshare admin karger, Ye Y., Guo J, Chen W., Wu X., Xu W., Huang X.   +6 more
openalex   +1 more source

Loss of vision as the first manifestation of amyloid light-chain amyloidosis. [PDF]

EJHaem
van de Donk NWCJ, Huysentruyt C, Dhooge MRP.   +2 more
europepmc   +1 more source

Outcomes of BTD vs. BCD as initial treatment of renal amyloid light-chain amyloidosis: a retrospective cohort study in China. [PDF]

Ren Fail
Li S, He W, Yau HH, Xie J, Zhu Y, Chen X, Zhang S, Zhang Y, Liao P, Liu H, Li L, Zhong L, Wang W.   +12 more
europepmc   +1 more source

Treatment Approach for Advanced Systemic Light Chain Amyloidosis: A Case Report. [PDF]

Cureus
Hachem MAM, Nasreddine GM, Farhat S, Hammoud ZM, Saad F, Saad WA.   +5 more
europepmc   +1 more source

Venetoclax Plus CyBorD Induction Therapy and Venetoclax Maintenance Treatment for Immunoglobulin Light Chain Amyloidosis with t(11;14) Translocation. [PDF]

Curr Oncol
Garami G, Obajed Al-Ali O, Virga I, Gulyás A, Bedekovics J, Tornai I, Illés Á, Magyari F.   +7 more
europepmc   +1 more source

Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis.

JAMA Oncol
Muchtar E, Wisniowski B, Geyer S, Palladini G, Milani P, Merlini G, Schönland S, Veelken K, Hegenbart U, Leung N, Dispenzieri A, Kumar SK, Kastritis E, Dimopoulos MA, Liedtke M, Ulloa P, Sanchorawala V, Szalat R, Dooley K, Landau H, Petrlik E, Lentzsch S, Coltoff A, Bladé J, Cibeira MT, Cohen O, Foard D, Gillmore J, Lachmann H, Wechalekar A, Gertz MA.   +30 more
europepmc   +1 more source

[Immunoglobulin light-chain type amyloidosis].

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1995
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Light-chain cardiac amyloidosis

Current Problems in Cancer, 2017
Cardiac amyloidosis is an underrecognized condition, in which delays to diagnosis have great implications on management options, prognosis, and morbidity. Once cardiac tissue is infiltrated by amyloid fibrils, there is a cascade of pathologic changes that can display an array of clinical manifestations, from impaired relaxation of the ventricular ...
Anit K, Mankad, Isata, Sesay, Keyur B, Shah   +2 more
openaire   +2 more sources

Immunoglobulin light chain amyloidosis

Expert Review of Hematology, 2013
Primary light chain amyloidosis is the most common form of systemic amyloidosis and is caused by misfolded light chains that cause proteotoxicity and rapid decline of vital organ function. Early diagnosis is essential in order to deliver effective therapy and prevent irreversible organ damage.
MERLINI, GIAMPAOLO, Comenzo RL, Seldin DC, Wechalekar A, Gertz MA   +4 more
openaire   +3 more sources